Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine group C conjugate - Pfizer

Drug Profile

Meningococcal vaccine group C conjugate - Pfizer

Alternative Names: Meningococcal vaccine group C conjugate - Baxter; NeisVac; NeisVac-C

Latest Information Update: 24 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator North American Vaccine
  • Developer Baxter International; Pfizer
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal group C infections

Most Recent Events

  • 07 Apr 2015 The vaccine is approved for Meningococcal group C infections in Colombia
  • 30 Jul 2014 Pfizer acquires Baxter's commercial vaccine business, including meningococcal vaccine group C conjugate NeisVac-C
  • 18 Feb 2013 Discontinued - Phase-III for Meningococcal group C infections in USA (IM)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top